Heterogeneous intimate admixtures of sulfated heparinic polysaccharides,
well suited for the prophylaxis/treatment of acute thrombotic episodes in a human
patient, comprise immixture of sulfated polysaccharides having a weight average
molecular weight less than that of heparin and which include from 9% to 20% of
polysaccharide chains having a molecular weight less than 2,000 daltons and from
5% to 20% of polysaccharide chains having a molecular weight greater than 8,000
daltons, the ratio between the weight average molecular weight and the number average
molecular weight thereof ranging from 1.3 to 1.6.
